In the last decade, several tyrosine kinase inhibitors (TKIs), which disrupt pathways involved in the proliferation and tumorigenesis of thyroid cancer, have been extensively studied. | SoLAT Sorafenib Lenvatinib alternating treatment A new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer